Who are dapagliflozin and saxagliptin's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Inpefa, Brenzavvy, Jardiance, Farxiga, Invokana, SAXAGLIPTIN.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/dapagliflozin-and-saxagliptin.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-17 · How we verify

dapagliflozin and saxagliptin — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

dapagliflozin and saxagliptin (dapagliflozin and saxagliptin) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Sodium-Glucose Cotransporter 2 Inhibitor [EPC].

marketed Sodium-Glucose Cotransporter 2 Inhibitor [EPC] Small molecule Live · refreshed every 30 min

Target snapshot

dapagliflozin and saxagliptin (dapagliflozin and saxagliptin) — AstraZeneca.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
dapagliflozin and saxagliptin TARGET	dapagliflozin and saxagliptin	AstraZeneca	marketed	Sodium-Glucose Cotransporter 2 Inhibitor [EPC]
Inpefa	SOTAGLIFLOZIN	Lexicon Pharms Inc	marketed	Sodium-Glucose Cotransporter 2 Inhibitor [EPC]	Sodium/glucose cotransporter 2	2023-01-01
Brenzavvy	BEXAGLIFLOZIN	Theracosbio	marketed	Sodium-Glucose Cotransporter 2 Inhibitor [EPC]	SGLT2	2023-01-01
Jardiance	empagliflozin	Boehringer Ingelheim	marketed	Sodium-Glucose Cotransporter 2 Inhibitor [EPC]	SGLT2	2014-01-01
Farxiga	DAPAGLIFLOZIN	AstraZeneca	marketed	Sodium-Glucose Cotransporter 2 Inhibitor	Sodium/glucose cotransporter 2	2014-01-01
Invokana	CANAGLIFLOZIN	Johnson & Johnson	marketed	Sodium-Glucose Cotransporter 2 Inhibitor	Sodium/glucose cotransporter 2	2013-01-01
SAXAGLIPTIN	SAXAGLIPTIN		marketed	Sodium-Glucose Cotransporter 2 Inhibitor [EPC]

Recent regulatory actions (last 90 days)

2026-04-06 — Farxiga · FDA · approved · US · AstraZeneca
2026-04-06 — Farxiga · FDA · approved · US · AstraZeneca
2026-04-06 — Farxiga · FDA · approved · US · AstraZeneca
2026-04-06 — Farxiga · FDA · approved · US · AstraZeneca
2026-04-06 — Farxiga · FDA · approved · US · AstraZeneca
2026-04-06 — dapagliflozin and saxagliptin · FDA · approved · US · AstraZeneca
2026-04-06 — SAXAGLIPTIN · FDA · approved · US

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Sodium-Glucose Cotransporter 2 Inhibitor [EPC] class)

· 1 drug in this class
AJANTA PHARMA LTD · 1 drug in this class
AstraZeneca · 1 drug in this class
Boehringer Ingelheim · 1 drug in this class
Lexicon Pharms Inc · 1 drug in this class
Theracosbio · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). dapagliflozin and saxagliptin — Competitive Intelligence Brief. https://druglandscape.com/ci/dapagliflozin-and-saxagliptin. Accessed 2026-05-17.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab